Kim Y, Kim J, Hanh B, Kim S, Kim H, Kim Y, et al. The Peroxisome Proliferator-Activated Receptor α- Agonist Gemfibrozil Promotes Defense Against Mycobacterium abscessus Infections. Cells. 2020;9: pubmed publisher

Patel D, Roy A, Kundu M, Jana M, Luan C, Gonzalez F, et al. Aspirin binds to PPARα to stimulate hippocampal plasticity and protect memory. Proc Natl Acad Sci U S A. 2018;115:E7408-E7417 pubmed publisher

Cizkova K, Steigerova J, Gursky J, Ehrmann J. Stimulating effect of normal-dosing of fibrates on cell proliferation: word of warning. Lipids Health Dis. 2016;15:164 pubmed

Becerra Herrera M, Honda L, Richter P. Ultra-high-performance liquid chromatography-Time-of-flight high resolution mass spectrometry to quantify acidic drugs in wastewater. J Chromatogr A. 2015;1423:96-103 pubmed publisher

Jafri K, Taylor L, Nezamzadeh M, Baker J, Mehta N, Bartels C, et al. Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting. BMC Musculoskelet Disord. 2015;16:237 pubmed publisher

Peyrusson F, Butler D, Tulkens P, Van Bambeke F. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 m. Antimicrob Agents Chemother. 2015;59:5747-60 pubmed publisher

Tatachar A, Pio M, Yeung D, Moss E, Chow D, Boatright S, et al. Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis. J Clin Lipidol. 2015;9:326-33 pubmed publisher

Wu J, Cheng Z, Chen H, Zhang G, He S, Liu S, et al. The significant inhibition on CYP3A caused by radix Aconiti single herb is not observed in the Wutou decoction: The necessity of combination therapy of radix Aconiti. J Ethnopharmacol. 2015;170:251-4 pubmed publisher

Grabacka M, Waligórski P, Zapata A, Blake D, Wyczechowska D, Wilk A, et al. Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier. J Physiol Pharmacol. 2015;66:233-47 pubmed

Moody D, Liu F, Fang W. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism. J Anal Toxicol. 2015;39:374-86 pubmed publisher

Li P, Li Z, Beck W, Callahan P, Terry A, Bar Peled M, et al. Bio-generation of stable isotope-labeled internal standards for absolute and relative quantitation of phase II drug metabolites in plasma samples using LC-MS/MS. Anal Bioanal Chem. 2015;407:4053-63 pubmed publisher

Duncan K, Vandergrift G, Krogh E, Gill C. Ionization suppression effects with condensed phase membrane introduction mass spectrometry: methods to increase the linear dynamic range and sensitivity. J Mass Spectrom. 2015;50:437-43 pubmed publisher

Chen F, Gong Z, Kelly B. Rapid analysis of pharmaceuticals and personal care products in fish plasma micro-aliquots using liquid chromatography tandem mass spectrometry. J Chromatogr A. 2015;1383:104-11 pubmed publisher

Kazmi F, Barbara J, Yerino P, Parkinson A. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab Dispos. 2015;43:523-33 pubmed publisher

Dodgen L, Ueda A, Wu X, Parker D, Gan J. Effect of transpiration on plant accumulation and translocation of PPCP/EDCs. Environ Pollut. 2015;198:144-53 pubmed publisher

Miller T, McEneff G, Brown R, Owen S, Bury N, Barron L. Pharmaceuticals in the freshwater invertebrate, Gammarus pulex, determined using pulverised liquid extraction, solid phase extraction and liquid chromatography-tandem mass spectrometry. Sci Total Environ. 2015;511:153-60 pubmed publisher

Kalasekar S, Zacharia E, Kessler N, Ducharme N, Gustafsson J, Kakadiaris I, et al. Identification of environmental chemicals that induce yolk malabsorption in zebrafish using automated image segmentation. Reprod Toxicol. 2015;55:20-9 pubmed publisher

Mason R, Jacob R. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim Biophys Acta. 2015;1848:502-9 pubmed publisher

Ito Y, Fukami T, Yokoi T, Nakajima M. An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. Drug Metab Dispos. 2014;42:2109-16 pubmed publisher

Bonfá G, Benevides L, Souza M, Fonseca D, Mineo T, Rossi M, et al. CCR5 controls immune and metabolic functions during Toxoplasma gondii infection. PLoS ONE. 2014;9:e104736 pubmed publisher

Krkošek W, Peldszus S, Huck P, Gagnon G. Formation kinetics of gemfibrozil chlorination reaction products: analysis and application. Water Environ Res. 2014;86:654-62 pubmed

Sonawane P, Cho H, Tagde A, Verlekar D, Yu A, Reynolds C, et al. Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br J Pharmacol. 2014;171:5330-44 pubmed publisher

Martin J, Santos J, Aparicio I, Alonso E. Pharmaceutically active compounds in sludge stabilization treatments: anaerobic and aerobic digestion, wastewater stabilization ponds and composting. Sci Total Environ. 2015;503-504:97-104 pubmed publisher

Kan C, Singh A, Stafforini D, Azhar S, Liu J. Arachidonic acid downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and proteasomal degradation. J Lipid Res. 2014;55:1657-67 pubmed publisher

Vildhede A, Karlgren M, Svedberg E, Wisniewski J, Lai Y, Norén A, et al. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos. 2014;42:1210-8 pubmed publisher

Yang G, Yen C, Wang C. Monitoring and removal of residual phthalate esters and pharmaceuticals in the drinking water of Kaohsiung City, Taiwan. J Hazard Mater. 2014;277:53-61 pubmed publisher

Jinno N, Tagashira M, Tsurui K, Yamada S. Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes. Xenobiotica. 2014;44:677-86 pubmed publisher

Galus M, Rangarajan S, Lai A, Shaya L, Balshine S, Wilson J. Effects of chronic, parental pharmaceutical exposure on zebrafish (Danio rerio) offspring. Aquat Toxicol. 2014;151:124-34 pubmed publisher

. Summaries for patients. Screening, monitoring, and treatment of early stage chronic kidney disease: recommendations from the American College of Physicians. Ann Intern Med. 2013;159:I-28 pubmed

Qaseem A, Hopkins R, Sweet D, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159:835-47 pubmed

Muñoz M, Liu W, Delaney J, Brown E, Mugavero M, Mathews W, et al. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr. 2013;64:254-60 pubmed publisher

Bayen S, Zhang H, Desai M, Ooi S, Kelly B. Occurrence and distribution of pharmaceutically active and endocrine disrupting compounds in Singapore's marine environment: influence of hydrodynamics and physical-chemical properties. Environ Pollut. 2013;182:1-8 pubmed publisher

Sierra Villar A, Calpena Campmany A, Bellowa L, Trenchs M, Naveros B. Validated spectrofluorometric method for determination of gemfibrozil in self nanoemulsifying drug delivery systems (SNEDDS). Spectrochim Acta A Mol Biomol Spectrosc. 2013;113:22-7 pubmed publisher

Kennedy M, Jellerson K, Snow M, Zacchetti M. Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. Paediatr Drugs. 2013;15:335-42 pubmed publisher

Filppula A, Tornio A, Niemi M, Neuvonen P, Backman J. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin Pharmacol Ther. 2013;94:383-93 pubmed publisher

Cziraky M, Willey V, McKenney J, Kamat S, Fisher M, Guyton J, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013;7:102-8 pubmed publisher

Varma M, Lai Y, Kimoto E, Goosen T, El Kattan A, Kumar V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res. 2013;30:1188-99 pubmed publisher

Yu Y, Liu Y, Wu L. Sorption and degradation of pharmaceuticals and personal care products (PPCPs) in soils. Environ Sci Pollut Res Int. 2013;20:4261-7 pubmed publisher

Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 2012;8:1549-63 pubmed publisher

Kudo T, Hisaka A, Sugiyama Y, Ito K. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. Drug Metab Dispos. 2013;41:362-71 pubmed publisher

Ghosh A, Corbett G, Gonzalez F, Pahan K. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor ?: implications for late infantile Batten disease therapy. J Biol Chem. 2012;287:38922-35 pubmed publisher

Hoppe Jones C, Dickenson E, Drewes J. The role of microbial adaptation and biodegradable dissolved organic carbon on the attenuation of trace organic chemicals during groundwater recharge. Sci Total Environ. 2012;437:137-44 pubmed publisher

Trinh T, Van den Akker B, Stuetz R, Coleman H, Le Clech P, Khan S. Removal of trace organic chemical contaminants by a membrane bioreactor. Water Sci Technol. 2012;66:1856-63 pubmed publisher

Lee C, Huang K, Lin C, Tsai T, Shih H. A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates. ScientificWorldJournal. 2012;2012:392734 pubmed publisher

Skolness S, Durhan E, Jensen K, Kahl M, Makynen E, Villeneuve D, et al. Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas). Environ Toxicol Chem. 2012;31:2615-24 pubmed publisher

Jana M, Mondal S, Gonzalez F, Pahan K. Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-?. J Biol Chem. 2012;287:34134-48 pubmed publisher

Mohagheghi F, Khalaj L, Ahmadiani A, Rahmani B. Gemfibrozil pretreatment affecting antioxidant defense system and inflammatory, but not Nrf-2 signaling pathways resulted in female neuroprotection and male neurotoxicity in the rat models of global cerebral ischemia-reperfusion. Neurotox Res. 2013;23:225-37 pubmed publisher

Shaikh Q, Kamal A. HDL cholesterol--how do I raise my patients good cholesterol?. J Pak Med Assoc. 2012;62:623-4 pubmed

Corbett G, Roy A, Pahan K. Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. J Immunol. 2012;189:1002-13 pubmed publisher

Ghosh A, Pahan K. Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. J Biol Chem. 2012;287:27189-203 pubmed publisher

Varma M, Lai Y, Feng B, Litchfield J, Goosen T, Bergman A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res. 2012;29:2860-73 pubmed publisher

Aquilante C, Kosmiski L, Bourne D, Bushman L, Daily E, Hammond K, et al. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013;75:217-26 pubmed publisher

Miglio G, Rosa A, Rattazzi L, Grange C, Camussi G, Fantozzi R. Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action. Br J Pharmacol. 2012;167:641-53 pubmed publisher

Alford J, Saseen J, Allen R, Nair K. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Pharmacotherapy. 2012;32:623-30 pubmed publisher

Hoose S, Duran C, Malik I, Eslamfam S, Shasserre S, Downing S, et al. Systematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetine. PLoS ONE. 2012;7:e36503 pubmed publisher

Nicolas J, Chanteux H, Rosa M, Watanabe S, Stockis A. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012;40:1466-72 pubmed publisher

Sharma P, Butters C, Smith V, Elsby R, Surry D. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci. 2012;47:244-55 pubmed publisher

Jana M, Pahan K. Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome proliferator-activated receptor β. Neurochem Res. 2012;37:1718-29 pubmed publisher

Villar A, Naveros B, Campmany A, Trenchs M, Rocabert C, Bellowa L. Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil. Int J Pharm. 2012;431:161-75 pubmed publisher

Bulloch D, Lavado R, Forsgren K, Beni S, Schlenk D, Larive C. Analytical and biological characterization of halogenated gemfibrozil produced through chlorination of wastewater. Environ Sci Technol. 2012;46:5583-9 pubmed publisher

Cooper J, Hwang K, Singh H, Wang D, Reynolds C, Curley R, et al. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol. 2011;163:1263-75 pubmed publisher

Roy A, Pahan K. Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol. 2009;31:339-51 pubmed publisher

Dixon D, Williams V. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy. 2009;29:744-8 pubmed publisher

Zgoda M, Nachajski M, Kołodziejczyk M, Woskowicz M, Lukosek M. Solubilizing properties of new surface-active agents, products of selective oxyethylation of cholic acid. Part I. Polim Med. 2007;37:21-38 pubmed

Roca B, Calvo B, Monferrer R. Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy. Ann Pharmacother. 2002;36:730-1 pubmed

Sirvent A, Cabezuelo J, Enriquez R, Amoros F, Gonzalez C, Reyes A. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination]. Nefrologia. 2001;21:497-500 pubmed

Doggrell S. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more. Expert Opin Pharmacother. 2001;2:1187-9 pubmed

de Arriba Méndez J, Gomez Merino E, Sáez Barcelona J, Sáez Méndez L. [Severe rhabdomyolysis associated with cerivastatin and gemfibrozil]. Med Clin (Barc). 2001;117:278-9 pubmed

Lau T, Leachman D, Lufschanowski R. Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case. Tex Heart Inst J. 2001;28:142-5 pubmed

Tada N. [Gemfibrozil: new aspects in clinical use]. Nihon Rinsho. 2001;59 Suppl 3:625-30 pubmed

. Gemfibrozil. IARC Monogr Eval Carcinog Risks Hum. 1996;66:427-44 pubmed

Spencer C, Barradell L. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs. 1996;51:982-1018 pubmed

Todd P, Ward A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs. 1988;36:314-39 pubmed

Zimetbaum P, Frishman W, Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol. 1991;31:25-37 pubmed

Magarian G, Lucas L, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med. 1991;151:1873-4 pubmed

Ebner F. [Gemfibrozil in the differential therapy of disorders of fat metabolism]. Fortschr Med. 1992;110:523-6 pubmed

Napoli C, Lepore S, Ambrosio G, Chiariello M. [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. Cardiologia. 1992;37:761-8 pubmed